Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting

B BOSTON, April 16, 2026 /PRNewswire/ —  Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing brain-penetrant small molecule therapies for neurodegenerative diseases, today announced…
posteditor
posteditor
Articles: 16137

Other News